GlassScriptPhysician profile
David S Robbins
NPI 1982706321
$954.30
in general payments reported to CMS, 2019-2025
15 companies · $24.68 in 2025
The $24.68 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.80 · 2020: $81.39 · 2021: $185 · 2022: $146 · 2023: $270 · 2024: $157 · 2025: $24.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $236.14 | 2023-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $211.62 | 2020-2024 | |
| Abbvie INC. | $175.69 | 2019-2023 | Lo Loestrin Fe |
| Agile Therapeutics, INC. | $73.46 | 2021-2024 | Twirla |
| Hologic Sales and Service, LLC | $53.03 | 2022 | |
| Organon LLC | $31.44 | 2022-2024 | |
| Coopersurgical, INC. | $28.17 | 2023 | Summit Doppler |
| Ethicon US, LLC | $24.93 | 2019 | |
| Octapharma USA, INC. | $24.68 | 2025 | Fibryga |
| Roche Diagnostics Corporation | $24.47 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $18.23 | 2023 | Bd Onclarity |
| Alexion Pharmaceuticals, INC. | $14.00 | 2019 | |
| Conmed Corporation | $13.74 | 2020 | |
| Channel Medsystems, INC. | $13.38 | 2023 | |
| Dysis Medical, INC. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.